Accordingly, given our preliminary results showcasing specific CDK mutagenic patterns to shape therapeutic sensitivity to CDK4/6i, we sought to map our findings in patients affected by HR+/HER2- breast cancer, and determine whether the behavior of these mutations in base editing sensor tiling screens was correlated with clinical outcomes in those treated with CDK4/6 inhibitors. The gene discussed is ERBB2; the disease is breast cancer.